MEMORANDUM & OPINION Defendants Safe Chain Solutions, LLC, Charles Boyd, and Patrick Boyd (collectively, “Safe Chain”) request that the Court enter an order compelling Plaintiffs Gilead Sciences, LLC, Gilead Sciences Ireland UC, and Gilead Sciences LLC (collectively, “Gilead”) to respond to interrogatories and document requests and also produce witnesses for depositions in connection with a purported wide-ranging scheme alleged by Gilead in the matter styled Gilead Sciences, Inc. v. AJC Medical Group, Inc., No. 1:20-cv-24523 (S.D. Fla.) (Cannon, J.) (“the Florida Scheme”). See Dkt. Nos. 1225, 1235 (collectively, “Safe Chain’s Motion to Compel”). For the reasons stated below, Safe Chain’s Motion to Compel is GRANTED IN PART and DENIED IN PART. Relevant Procedural Background Safe Chain’s Motion to Compel was filed, pursuant to the undersigned’s Individual Practices and Rules, as part of a joint submission by the parties on November 28, 2023 addressing a discovery dispute. See Dkt. No. 1225 (setting forth the positions of Safe Chain and Gilead). On December 1, 2023, during a hearing on a number of discovery-related issues, the Court deferred ruling on Safe Chain’s Motion to Compel. See Order, dated December 1, 2023; see also Dkt. No. 1236. The Court ordered Safe Chain to file a supplemental letter by December 4, 2023 clarifying its position as to why discovery should be granted related to the Florida Scheme. See Order, dated December 1, 2023. The Court also ordered Gilead to file a response by December 6, 2023. See id. Safe Chain supplemented the Motion to Compel with a separate letter, with attachments, filed on December 4, 2023. See Dkt. No. 1235. Gilead responded with its own letter, plus attachments, filed on December 6, 2023. See Dkt. No. 1238. Relevant Factual Background This action arises out of an alleged HIV drug counterfeiting ring involving three groups of participants: suppliers, distributors, and pharmacies. See Memorandum Decision and Order, Dkt. No. 781 at 2; see also Sixth Amended Complaint, Dkt. No. 1056
209-19. Gilead alleges that distributor defendants — including Safe Chain, a pharmaceutical distributor — sold Gilead-branded bottles repurposed with non-Gilead drugs, such as anti-psychotic medication, that do not treat HIV. Id. Gilead also alleges that defendants — including Safe Chain — sold thousands of Gilead-branded bottles with the correct Gilead medication but accompanied by fake government-required forms called “pedigrees.” Dkt. No.
